Vaximm combining VXM01 and Bavencio

Vaximm AG (Basel, Switzerland) will conduct two open-label trials evaluating its VXM01 in combination with PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK). Vaximm declined to provide a start date for the trials, which will enroll patients with glioblastoma or metastatic colorectal cancer (mCRC).

VXM01 is an oral T cell immunotherapy based on the recombinant, live, attenuated Salmonella typhi vaccine strain Ty21a that carries the VEGF receptor 2 (VEGFR-2; KDR/Flk-1) gene. The candidate has completed multiple Phase I trials in cancer. Bavencio has accelerated approval in the U.S. to treat Merkel cell and urothelial carcinomas...